Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

First patient treated in phase I trial of GL-ONC1

Feb. 7, 2013

Seattle Genetics begins two phase I trials of SGN-CD19A

Feb. 7, 2013

Therapeutic cervical cancer vaccine eradicates established tumors in mice

Feb. 7, 2013

Health Canada grants approval to Adcetris for two lymphoma indications

Feb. 4, 2013

Teva Pharmaceutical terminates agreements with CureTech

Feb. 4, 2013

Targovax includes first patient in phase I/II TG-01 study

Feb. 1, 2013

New MAbs described by Oxford BioTherapeutics

Feb. 1, 2013

Encouraging results from phase III study of obinutuzumab in CLL

Jan. 31, 2013

FDA clears IND application for ICT-140

Jan. 30, 2013

OncoPep begins phase I/IIa trial of multipeptide vaccine in smoldering multiple myeloma

Jan. 30, 2013

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...